|
Delayed
NSE India S.E.
01:35:52 30/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,841.30 INR | -1.27% |
|
-1.27% | +7.08% |
| 06:34am | Sun Pharma Plans $1.04 Billion via Rupee Bonds to Refinance Organon Bridge Loan | MT |
| 06:26am | Mayne Pharma Group Settles Patent Litigation With Sun Pharmaceutical Industries | MT |
| Market Cap | 4,47500Cr 4.66TCr 4.12TCr 3.89TCr 3.53TCr 6.62TCr 6.69TCr 47TCr 18TCr 2,28500Cr 18TCr 17TCr 7,35300Cr | P/E 2027 * |
34.4x | P/E 2028 * | 29.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,20400Cr 4.38TCr 3.87TCr 3.66TCr 3.32TCr 6.22TCr 6.28TCr 44TCr 17TCr 2,14700Cr 16TCr 16TCr 6,90800Cr | EV / Sales 2027 * |
6.46x | EV / Sales 2028 * | 5.67x |
| Free-Float |
44.39% | Yield 2027 * |
0.92% | Yield 2028 * | 1.07% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -1.68% | ||
| 1 week | -1.68% | ||
| Current month | -7.61% | ||
| 1 month | -7.61% | ||
| 3 months | -1.55% | ||
| 6 months | +4.35% | ||
| Current year | +6.63% |
| 1 week | 1,814.2 |  | 1,880 |
| 1 month | 1,814.2 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,583.7 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.66% | -1.68% | +15.02% | +60.65% | 4.66TCr | |
| +1.62% | +4.94% | +47.41% | +121.09% | 3.8TCr | |
| -3.02% | -0.44% | +18.65% | +90.66% | 1.25TCr | |
| -1.10% | -1.30% | -9.20% | +15.40% | 1.16TCr | |
| -0.19% | +0.19% | +18.18% | +137.44% | 892.01Cr | |
| +0.56% | -2.53% | +37.79% | -16.85% | 695.4Cr | |
| -0.56% | -2.14% | +26.79% | +38.31% | 693.18Cr | |
| -2.33% | -3.75% | +22.00% | +182.73% | 718.03Cr | |
| +0.30% | -3.94% | -49.55% | +1.01% | 494.63Cr | |
| +2.04% | +1.73% | +50.85% | +102.59% | 463.19Cr | |
| Average | -0.43% | -0.16% | +17.79% | +73.30% | 1.48TCr | |
| Weighted average by Cap. | -0.50% | +0.87% | +22.84% | +80.29% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 65TCr 678.55Cr 598.82Cr 566.58Cr 513.83Cr 963.34Cr 972.84Cr 6.8TCr 2.62TCr 33TCr 2.55TCr 2.49TCr 1,07000Cr | 73TCr 760.25Cr 670.92Cr 634.79Cr 575.69Cr 1.08TCr 1.09TCr 7.62TCr 2.93TCr 37TCr 2.85TCr 2.79TCr 1,19900Cr |
| Net income | 13TCr 134.82Cr 118.98Cr 112.57Cr 102.09Cr 191.4Cr 193.29Cr 1.35TCr 520.46Cr 6.61TCr 506.24Cr 495.22Cr 21TCr | 15TCr 160.05Cr 141.25Cr 133.64Cr 121.2Cr 227.23Cr 229.47Cr 1.6TCr 617.89Cr 7.84TCr 601Cr 587.92Cr 25TCr |
| Net Debt | -27TCr -282.07Cr -248.93Cr -235.52Cr -213.59Cr -400.45Cr -404.4Cr -2.83TCr -1.09TCr -14TCr -1.06TCr -1.04TCr -44TCr | -34TCr -352.68Cr -311.24Cr -294.48Cr -267.06Cr -500.69Cr -505.64Cr -3.53TCr -1.36TCr -17TCr -1.32TCr -1.3TCr -56TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | ₹1,841.30 | -1.27% | 12,14,980 |
| 29/26/29 | ₹1,865.00 | +1.47% | 30,83,083 |
| 28/26/28 | ₹1,838.00 | -0.77% | 9,47,719 |
| 25/26/25 | ₹1,852.20 | +0.12% | 6,83,246 |
| 24/26/24 | ₹1,849.90 | -0.81% | 17,42,885 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
